109 related articles for article (PubMed ID: 24789807)
1. XAV939 inhibits the stemness and migration of neuroblastoma cancer stem cells via repression of tankyrase 1.
Tian X; Hou W; Bai S; Fan J; Tong H; Xu H
Int J Oncol; 2014 Jul; 45(1):121-8. PubMed ID: 24789807
[TBL] [Abstract][Full Text] [Related]
2. XAV939 promotes apoptosis in a neuroblastoma cell line via telomere shortening.
Tian X; Hou W; Bai S; Fan J; Tong H; Bai Y
Oncol Rep; 2014 Nov; 32(5):1999-2006. PubMed ID: 25190315
[TBL] [Abstract][Full Text] [Related]
3. XAV939, a tankyrase 1 inhibitior, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/β-catenin signaling pathway.
Tian XH; Hou WJ; Fang Y; Fan J; Tong H; Bai SL; Chen Q; Xu H; Li Y
J Exp Clin Cancer Res; 2013 Dec; 32(1):100. PubMed ID: 24308762
[TBL] [Abstract][Full Text] [Related]
4. Role of stemness-related molecules in neuroblastoma.
Kamijo T
Pediatr Res; 2012 Apr; 71(4 Pt 2):511-5. PubMed ID: 22430387
[TBL] [Abstract][Full Text] [Related]
5. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification.
Takenobu H; Shimozato O; Nakamura T; Ochiai H; Yamaguchi Y; Ohira M; Nakagawara A; Kamijo T
Oncogene; 2011 Jan; 30(1):97-105. PubMed ID: 20818439
[TBL] [Abstract][Full Text] [Related]
6. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
7. Tideglusib attenuates growth of neuroblastoma cancer stem/progenitor cells in vitro and in vivo by specifically targeting GSK-3β.
Bahmad HF; Chalhoub RM; Harati H; Bou-Gharios J; Assi S; Ballout F; Monzer A; Msheik H; Araji T; Elajami MK; Ghanem P; Chamaa F; Kadara H; Abou-Antoun T; Daoud G; Fares Y; Abou-Kheir W
Pharmacol Rep; 2021 Feb; 73(1):211-226. PubMed ID: 33030673
[TBL] [Abstract][Full Text] [Related]
8. Neuroblastoma stem cells - mechanisms of chemoresistance and histone deacetylase inhibitors.
Khalil MA; Hrabeta J; Cipro S; Stiborova M; Vicha A; Eckschlager T
Neoplasma; 2012; 59(6):737-46. PubMed ID: 22862175
[TBL] [Abstract][Full Text] [Related]
9. Genotype analysis of tumor-initiating cells expressing CD133 in neuroblastoma.
Cournoyer S; Nyalendo C; Addioui A; Belounis A; Beaunoyer M; Aumont A; Teira P; Duval M; Fernandes K; Fetni R; Haddad E; Sartelet H
Genes Chromosomes Cancer; 2012 Aug; 51(8):792-804. PubMed ID: 22514116
[TBL] [Abstract][Full Text] [Related]
10. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
12. Significance of hematopoietic surface antigen CD34 in neuroblastoma prognosis and the genetic landscape of CD34-expressing neuroblastoma CSCs.
Aravindan N; Somasundaram DB; Herman TS; Aravindan S
Cell Biol Toxicol; 2021 Jun; 37(3):461-478. PubMed ID: 32979173
[TBL] [Abstract][Full Text] [Related]
13. Analysis of stemness gene expression and CD133 abnormal methylation in neuroblastoma cell lines.
Schiapparelli P; Enguita-Germán M; Balbuena J; Rey JA; Lázcoz P; Castresana JS
Oncol Rep; 2010 Nov; 24(5):1355-62. PubMed ID: 20878131
[TBL] [Abstract][Full Text] [Related]
14. CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).
Choijamts B; Jimi S; Kondo T; Naganuma Y; Matsumoto T; Kuroki M; Iwasaki H; Emoto M
Stem Cells; 2011 Oct; 29(10):1485-95. PubMed ID: 21919130
[TBL] [Abstract][Full Text] [Related]
15. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.
Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL
Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126
[TBL] [Abstract][Full Text] [Related]
16. Enhanced cell growth and tumorigenicity of rat glioma cells by stable expression of human CD133 through multiple molecular actions.
Fang KM; Lin TC; Chan TC; Ma SZ; Tzou BC; Chang WR; Liu JJ; Chiou SH; Yang CS; Tzeng SF
Glia; 2013 Sep; 61(9):1402-17. PubMed ID: 23832679
[TBL] [Abstract][Full Text] [Related]
17. Tankyrase 1 inhibitior XAV939 increases chemosensitivity in colon cancer cell lines via inhibition of the Wnt signaling pathway.
Wu X; Luo F; Li J; Zhong X; Liu K
Int J Oncol; 2016 Apr; 48(4):1333-40. PubMed ID: 26820603
[TBL] [Abstract][Full Text] [Related]
18. The binding mechanism of a novel nicotinamide isostere inhibiting with TNKSs: a molecular dynamic simulation and binding free energy calculation.
Feng TT; Zhang YJ; Chen H; Fan S; Han JG
J Biomol Struct Dyn; 2016; 34(3):517-28. PubMed ID: 25933061
[TBL] [Abstract][Full Text] [Related]
19. Functional sphere profiling reveals the complexity of neuroblastoma tumor-initiating cell model.
Coulon A; Flahaut M; Mühlethaler-Mottet A; Meier R; Liberman J; Balmas-Bourloud K; Nardou K; Yan P; Tercier S; Joseph JM; Sommer L; Gross N
Neoplasia; 2011 Oct; 13(10):991-1004. PubMed ID: 22028624
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD133 antigen in cancer.
Ferrandina G; Petrillo M; Bonanno G; Scambia G
Expert Opin Ther Targets; 2009 Jul; 13(7):823-37. PubMed ID: 19530986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
